Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- context label "adults" assertion.
- association label "In patients with Li-NDI, off label therapy with amiloride can be useful." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "TCAs have been used to treat chronic low back pain for decades and have been repeatedly shown to be more effective than placebo in reducing pain severity" assertion.
- HP_0003419 label "Low Back pain" assertion.
- HP_0003419 label "Low back pain" assertion.
- context label "adults" assertion.
- association label "TCAs have been used to treat chronic low back pain for decades and have been repeatedly shown to be more effective than placebo in reducing pain severity" assertion.
- association label "Patients with irritable bowel syndrome have long been known to benefit from TCAs; the number needed to treat for symptomatic benefit over placebo is 3.5" assertion.
- context label "adults" assertion.
- association label "Information extracted from Table 2." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression." assertion.
- context label "Adults" assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia. Table 2 contains off-label drugs prescribed." assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia" assertion.
- context label "Adults" assertion.
- association label "Antidepressants, particularly TCAs and SNRIs, have also found their application in relieving pain related with fibromyalgia" assertion.
- context label "Adults" assertion.
- MONDO_0024317 label "chronic pain syndrome" assertion.
- MONDO_0024317 label "chronic pain syndrome" assertion.
- MONDO_0024317 label "chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- MONDO_0024317 label "Chronic pain syndrome" assertion.
- association label "NaN" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- MONDO_0005582 label "binge eating disorder" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "Premature ejaculation (disease)" assertion.
- MONDO_0001780 label "premature ejaculation (disorder)" assertion.
- MONDO_0001780 label "premature ejaculation (disorder)" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- association label "Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019)." assertion.
- context label "Adults" assertion.
- association label "Drugs from all five classes of antidepressants have been investigated for use as smoking cessation aids (Shoaib and Buhidma, 2018). The second generation TCA nortriptyline is regarded as the most promising alternative to bupropion. This antidepressant mainly inhibits noradrenaline and serotonin transporters (Kripke, 2005). Antidepressants of the SSRI category are not effective, however, suggesting that serotonin does not play the main role in smoking addiction (Hughes et al., 2014)." assertion.
- context label "Adults" assertion.
- NCIT_C17427 label "smoking cessation" assertion.
- context label "Adults" assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2 contains information on trazodone and mirtazapine). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "The SGA olanzapine is considered the most appropriate, followed by quetiapine and aripiprazole. Although off-label prescription of SGAs represents a common clinical practice in accordance with a worldwide trend, the use of long-acting injection formulations was considered inappropriate by 69% of psychiatrists in our sample. Attitudes on off-label use of Aripiprazole in the treatment of BPD: Highly inappropriate = 44 (21.8%); Innapropriate = 38 (18.8%); Doubt = 74 (36.6%); Appropriate = 43 (21.3%); Highly appropriate = 3 (1.5%) " assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Clozapine in the treatment of BPD: Highly inappropriate = 115 (56.9%); Innapropriate = 32 (15.8%); Doubt = 42 (20.9%); Appropriate = 13 (6.4%); Highly appropriate = 0 (0%) " assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Paliperidone in the treatment of BPD: Highly inappropriate = 81 (40.1%); Innapropriate = 32 (15.8%); Doubt = 66 (32.7%); Appropriate = 20 (9.9%); Highly appropriate = 3 (1.5%) " assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Risperidone in the treatment of BPD: Highly inappropriate = 51 (25.2%); Innapropriate = 31 (15.3%); Doubt = 90 (44.6%); Appropriate = 28 (13.9%); Highly appropriate = 2 (1.0%) " assertion.
- context label "Adults" assertion.
- association label "Hence, it is possible that its popularity in special populations is due to the fact that the unpleasant or unwanted effects of addiction substances are somehow soothed by quetiapine. Currently, quetiapine is tested in substance use disorders, showing some promise, but it is likely to be misused in certain contexts" assertion.
- context label "Adults" assertion.
- association label "This involves also off-label prescription of the drug as hypnotic, which is high, and this has been attributed to the off-label promotion of its prescription by its manufacturers, who were also fined for this (Monasterio & McKean, 2011a, 2011b; McKean & Monasterio, 2012); this probably ensued in increased demand for other than indicated conditions (Monasterio & McKean, 2013a). " assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- MONDO_0005090 label "schizophrenia" assertion.
- MONDO_0005090 label "schizophrenia" assertion.
- MONDO_0005090 label "schizophrenia" assertion.
- MONDO_0005090 label "schizophrenia" assertion.
- MONDO_0005090 label "Schizophrenia" assertion.
- MONDO_0005090 label "Manic bipolar affective disorder" assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- context label "Adults" assertion.
- association label "In addition to neuropathic pain, bupropion has also shown some effectiveness in treating chronic pain that is caused by inflammatory bowel disease (IBD)" assertion.
- context label "Adults" assertion.
- association label "Emerging research assesses the utility of venlafaxine in the management of chronic neuropathic pain." assertion.
- association label "With regard to the use of specific SGAs in BD, off-label aripiprazole was considered appropriate for depressive episodes by 46% of the psychiatrists, followed by olanzapine which was considered appropriate by 33.7%." assertion.
- context label "Adults" assertion.
- context label "Adults" assertion.